Analysts predict that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will announce $690.66 million in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Endo International’s earnings. The highest sales estimate is $732.10 million and the lowest is $660.80 million. Endo International posted sales of $700.53 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 1.4%. The business is scheduled to announce its next quarterly earnings report on Tuesday, May 14th.
According to Zacks, analysts expect that Endo International will report full year sales of $2.84 billion for the current financial year, with estimates ranging from $2.80 billion to $2.87 billion. For the next fiscal year, analysts anticipate that the company will report sales of $2.91 billion, with estimates ranging from $2.67 billion to $3.14 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, February 28th. The company reported $0.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.16. Endo International had a negative net margin of 35.00% and a negative return on equity of 337.13%. During the same quarter in the previous year, the business earned $0.77 earnings per share.
Several research analysts recently commented on the stock. ValuEngine upgraded shares of Endo International from a “sell” rating to a “hold” rating in a report on Tuesday. Canaccord Genuity set a $17.00 price target on shares of Endo International and gave the stock a “buy” rating in a research report on Friday, March 8th. BidaskClub lowered shares of Endo International from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. Svb Leerink lowered shares of Endo International from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 5th. Finally, Leerink Swann lowered shares of Endo International from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 5th. Fourteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $16.00.
Several institutional investors and hedge funds have recently modified their holdings of the company. Norges Bank bought a new position in Endo International during the 4th quarter worth approximately $21,218,000. Nordea Investment Management AB raised its holdings in Endo International by 23.0% during the 4th quarter. Nordea Investment Management AB now owns 129,200 shares of the company’s stock worth $943,000 after purchasing an additional 24,200 shares during the last quarter. Globeflex Capital L P raised its holdings in Endo International by 2.6% during the 4th quarter. Globeflex Capital L P now owns 214,135 shares of the company’s stock worth $1,563,000 after purchasing an additional 5,391 shares during the last quarter. Municipal Employees Retirement System of Michigan bought a new position in Endo International during the 4th quarter worth approximately $421,000. Finally, LMR Partners LLP bought a new position in Endo International during the 4th quarter worth approximately $442,000. 98.25% of the stock is currently owned by institutional investors.
ENDP traded up $0.01 during trading hours on Tuesday, hitting $8.42. 1,488,832 shares of the company’s stock were exchanged, compared to its average volume of 3,429,484. Endo International has a 1-year low of $5.27 and a 1-year high of $18.50. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 2.91 and a beta of 1.21.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Read More: Why is cost of goods sold important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.